

Curriculum Vitae - Letizia Gianoncelli, MD

PERSONAL INFORMATION

Name/surname: Letizia Gianoncelli, MD

Date of Birthday:

Citizenship: Italy

Phone: +39 – 0281844125

Mobile:

Email: letizia.gianoncelli@asst-santipaolocarlo.it

Work address: San Paolo Hospital, Via A. di Rudinì n 8, 20142 Milan – Italy

PROFESSIONAL EXPERIENCE AND CLINICAL ACTIVITY

2021 – Present Medical Oncologist, Division of Clinical Oncology, **San Paolo Hospital**, Milan – Dr. M Moroni

2018 – 2020 Medical Oncologist, Division of Thoracic Oncology, **European Institute of Oncology**, Milan – Prof. F de Marinis

2016-2018 Medical Oncologist, Division of Thoracic and Genitourinary Oncology, **Humanitas Gavazzeni**, Bergamo – Dr. G Beretta

2015 Resident in Medical Oncology, **Humanitas Cancer Center**, Milan - Prof. A Santoro

2013-2014 Fellow in Thoracic Oncology, Medical Oncology Division, **Gustave Roussy**, Villejuif – Prof. JC Soria

2010-2012 Resident in Medical Oncology, **Humanitas Cancer Center**, Milan - Prof. A Santoro

2009 Internship in Pharmacology Laboratory, **VU University Medical Center**, Amsterdam – Prof. GJ Peters

2005 Volunteer for the Vaccination and nutrition Program, **Institute for Indian Mother and Child**, Kolkata – Dr. KB Sujit.

EDUCATION AND COURSES

2016 Medical Oncology Residency Degree (70/70 cum laude) - University of Milan

2014 Diplôme Universitaire Européen de Recherche Translationnelle Et Clinique en Cancérologie (DUERTECC), Université Paris Sud – Prof E Deutsch

2014 Chemotherapy and medical cancer treatment course, Gustave Roussy, Villejuif – Prof. JC Soria

2009 Medical School Degree (110/110 cum laude) - University of Milan

Italian Medical Board License number: 41763 (Milan, 01/03/2010)

SCIENTIFIC AFFILIATIONS

European Society of Medical Oncology (ESMO)

Italian Association of Medical Oncology (AIOM)

Italian Association of Thoracic Oncology (AIOT)

European Thoracic Oncology Platform (ETOP)

Indexed PUBLICATIONS

1. Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. *Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial*. Lancet Oncol. 2021 Oct;22(10):1438-1447.
2. Petrocchi S, Janssens R, Oliveri S, Arnou R, Durosini I, Guidi P, Louis E, Vandeveld M, Nackaerts K, Smith MY, Galli G, de Marinis F, Gianoncelli L, Pravettoni G, Huys I. *What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences*. Front Pharmacol. 2021 Mar 4;12:602112.
3. de Marinis F, Attili I, Morganti S, Stati V, Spitaleri G, Gianoncelli L, Del Signore E, Catania C, Rampinelli C, Omodeo Salè E, Spaggiari L, Mastrilli F, Passaro A. *Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model*. Front Oncol. 2020 Apr 22;10:665.
4. Ceresoli GL, Gianoncelli L, Grosso F; STELLAR investigators. *Tumour Treating Fields for mesothelioma - Authors' reply*. Lancet Oncol. 2020 Jan;21(1):e10.
5. Gianoncelli L, Spitaleri G, Passaro A, Radice D, Fumagalli C, Del Signore E, Stati V, Catania CM, Guerini-Rocco E, Barberis M, DE Marinis F. *Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis*. Anticancer Res. 2020 Jan;40(1):427-433.
6. Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F. *Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial*. Lancet Oncol. 2019 Dec;20(12):1702-1709.
7. Passaro A, Gianoncelli L, Stati V, de Marinis F. *Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding*. Ann Transl Med. 2019 Jul;7(Suppl 3):S80.
8. Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E. *Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study*. Cancer Manag Res. 2017 Dec 7;9:789-800.
9. Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A. *Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy*. Cancer Med. 2017 Oct;6(10):2287-2296.
10. Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanella A, Ceresoli GL. *Clinical staging of malignant pleural mesothelioma: current perspectives*. Lung Cancer. 2017 Aug 18;8:127-139.
11. Finocchiaro G, Toschi L, Gianoncelli L, Baretta M, Santoro A. *Prognostic and predictive value of MET deregulation in non-small cell lung cancer*. Ann Transl Med. 2015 Apr;3(6):83.

12. Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A. *Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma*. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):667-75.
13. Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, Perrino M, Siracusano L, Di Tommaso L, Infante M, Aloisio M, Roncalli M, Scorsetti M, Jänne PA, Santoro A, Varella-Garcia M. *Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease*. PLoS One. 2014 Apr 15;9(4):e95303.
14. Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A. *Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma*. Lung Cancer. 2014 Jun;84(3):265-70.
15. Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A. *Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma*. Br J Cancer. 2013 Aug 6;109(3):552-8.
16. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ. *Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin*. Br J Cancer. 2011 Nov 8;105(10):1542-53.
17. Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, Santoro A. *Advances in the biology of malignant pleural mesothelioma*. Cancer Treat Rev. 2011 Nov; 37(7):543-58.
18. De Vincenzo F, Zucali PA, Ceresoli GL, Colombo P, Simonelli M, Lorenzi E, Perrino M, Gianoncelli L, De Sanctis R, Graziotti P, Santoro A. *Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma*. J Clin Oncol. 2011 Jun 20; 29(18):529-31.
19. Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. *Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin*. Clin Cancer Res. 2011 Apr 15;17(8):2581-90.
20. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A. *Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma*. Lung Cancer. 2011 Apr; 72(1):73-7.
21. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A. *Second-line treatment for malignant pleural mesothelioma*. Cancer Treat Rev. 2010 Feb; 36(1):24-32.

In compliance with the GDPR and Italian Legislative Decree no.196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.

Milano, 20/07/2022